Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10673413 | 0.85 | CYP1A2 (0.50) | CYP1A2PDGFRBPDGFRAPDE10AKDM1A | |
| SCHEMBL272166 | 0.80 | CYP1A2 (0.46) | CYP1A2PDGFRBPDGFRAPDE10AKDM1A | |
| SCHEMBL3820110 | 0.79 | CYP1A2 (0.52) | CYP1A2PDGFRBPDGFRAPDE10AKDM1A | |
| SCHEMBL151560 | 0.79 | CYP1A2 (0.57) | CYP1A2PDGFRBPDGFRAPDE10AKDM1A | |
| SCHEMBL5742532 | 0.79 | MGAM (0.47) | CYP1A2MGAMRAB9A | |
| SCHEMBL3396692 | 0.79 | CYP1A2 (0.55) | CYP1A2PDGFRBPDGFRAPDE10AKDM1A | |
| SCHEMBL28243569 | 0.78 | CYP1A2 (0.50) | CYP1A2PDGFRBPDGFRAPDE10AKDM1A | |
| SCHEMBL6115113 | 0.76 | TRPV1 (0.55) | CYP1A2PDGFRBPDGFRAPDE10AKDM1A | |
| SCHEMBL11179457 | 0.76 | CYP1A2 (0.41) | CYP1A2PDGFRBPDGFRAPDE10AKDM1A | |
| SCHEMBL6597946 | 0.76 | CYP1A2 (0.52) | CYP1A2PDGFRBPDGFRAPDE10AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087174-A1 | ARYL AND HETEROARYL SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087174-A1 | ARYL AND HETEROARYL SUBSTITUTED INDOLE COMPOUNDS | TLR7, TLR1, TLR9 | CYP1A2 1301/4885PDGFRB 243/4885PDGFRA 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.